Aperio Group’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | $151M | Buy |
1,407,649
+28,003
| +2% | +$2.69M | 0.45% | 38 |
|
|
2020
Q3 | $121M | Buy |
1,379,646
+75,503
| +6% | +$7.11M | 0.41% | 43 |
|
|
2020
Q2 | $128M | Buy |
1,304,143
+130,792
| +11% | +$11.5M | 0.47% | 38 |
|
|
2020
Q1 | $89.4M | Buy |
1,173,351
+82,349
| +8% | +$7.01M | 0.39% | 46 |
|
|
2019
Q4 | $96.6M | Buy |
1,091,002
+115,286
| +12% | +$9.57M | 0.35% | 50 |
|
|
2019
Q3 | $73.9M | Sell |
975,716
-51,146
| -5% | -$3.51M | 0.29% | 60 |
|
|
2019
Q2 | $74.7M | Buy |
1,026,862
+5,179
| +0.5% | +$407K | 0.31% | 57 |
|
|
2019
Q1 | $82.3M | Sell |
1,021,683
-2,682
| -0.3% | -$219K | 0.36% | 52 |
|
|
2018
Q4 | $94.4M | Buy |
1,024,365
+2,193
| +0.2% | +$193K | 0.48% | 35 |
|
|
2018
Q3 | $96.7M | Sell |
1,022,172
-905
| -0.1% | -$85.8K | 0.43% | 42 |
|
|
2018
Q2 | $94.8M | Buy |
1,023,077
+31,738
| +3% | +$3.1M | 0.45% | 32 |
|
|
2018
Q1 | $93.8M | Buy |
991,339
+47,732
| +5% | +$5.24M | 0.47% | 30 |
|
|
2017
Q4 | $91.3M | Buy |
943,607
+78,324
| +9% | +$7.38M | 0.46% | 34 |
|
|
2017
Q3 | $76.9M | Buy |
865,283
+37,333
| +5% | +$2.84M | 0.43% | 35 |
|
|
2017
Q2 | $60M | Buy |
827,950
+87,523
| +12% | +$5.88M | 0.37% | 48 |
|
|
2017
Q1 | $48.2M | Buy |
740,427
+1,533
| +0.2% | +$96.4K | 0.33% | 53 |
|
|
2016
Q4 | $46.3M | Sell |
738,894
-13,691
| -2% | -$836K | 0.35% | 48 |
|
|
2016
Q3 | $47.5M | Buy |
752,585
+37,055
| +5% | +$2.4M | 0.34% | 55 |
|
|
2016
Q2 | $44.3M | Buy |
715,530
+36,503
| +5% | +$2.22M | 0.35% | 59 |
|
|
2016
Q1 | $38.8M | Buy |
679,027
+108,530
| +19% | +$6.05M | 0.33% | 59 |
|
|
2015
Q4 | $33.8M | Sell |
570,497
-1,405
| -0.2% | -$80.9K | 0.31% | 66 |
|
|
2015
Q3 | $31.1M | Buy |
571,902
+45,290
| +9% | +$2.95M | 0.32% | 67 |
|
|
2015
Q2 | $35.4M | Buy |
526,612
+77,035
| +17% | +$5.03M | 0.37% | 53 |
|
|
2015
Q1 | $26.3M | Buy |
449,577
+21,317
| +5% | +$1.29M | 0.29% | 73 |
|
|
2014
Q4 | $28M | Buy |
428,260
+30,791
| +8% | +$1.94M | 0.35% | 53 |
|
|
2014
Q3 | $23M | Buy |
397,469
+23,379
| +6% | +$1.3M | 0.31% | 63 |
|
|
2014
Q2 | $21.1M | Buy |
374,090
+8,596
| +2% | +$451K | 0.31% | 65 |
|
|
2014
Q1 | $18.8M | Buy |
+365,494
| New | +$18.5M | 0.26% | 66 |
|
|
2013
Q4 | – | Sell |
-323,128
| Closed | -$15.9M | – | 58 |
|
|
2013
Q3 | $14.5M | Buy |
323,128
+17,428
| +6% | +$773K | 0.28% | 63 |
|
|
2013
Q2 | $12.6M | Buy |
+305,700
| New | +$13.4M | 0.3% | 59 |
|
Other funds holding ABBV
Aperio Group's ABBV Position: Q4 2020 in Review
Aperio Group increased its AbbVie (ABBV) stake by 2% in Q4 2020, buying an estimated $2.69M and bringing the position to 1,407,649 shares worth $151M. The position accounts for 0.45% of the portfolio, ranked #38.
Aperio Group first reported a position in ABBV in Q2 2013 and has held it in 30 quarters since. 2,598 funds tracked by Wall St. Rank hold ABBV as of Q4 2020.
- Aperio Group held 1,407,649 shares of AbbVie worth $151M as of Q4 2020.
- Aperio Group bought 28,003 AbbVie shares in Q4 2020, an estimated $2.69M.
- AbbVie made up 0.45% of Aperio Group's portfolio in Q4 2020, its #38 holding.
- Aperio Group first reported a position in AbbVie in Q2 2013 and has held it in 30 quarters since.
- 2,598 funds tracked by Wall St. Rank held AbbVie as of Q4 2020.
Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.